Overall, our findings provide evidence that shikimic acid has a hypolipogenic effect in HepG2 and 3T3-L1 cells via phosphorylation of AMPK/ACC and inhibition of MID1IP1 as a potential candidate for prevention or treatment of fatty liver and hyperlipidemia (Figure 6). Here, MID1IP1 is linked to Hepatic steatosis.